Setmelanotide, a melanocortin-4 receptor (MC4R) agonist, is the first FDA-approved treatment targeting hypothalamic leptin-melanocortin pathway defects in monogenic obesity syndromes. The gene discussed is MC4R; the disease is obesity disorder.